Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

Fibrolamellar hepatocellular carcinoma (FLC) is a rare and often lethal liver cancer with no proven effective systemic therapy. Inhibition of the antiapoptotic protein BCL-XL was found to synergize with a variety of systemic therapies in vitro using cells dissociated from patient-derived xenografts...

Descripción completa

Detalles Bibliográficos
Autores principales: Shebl, Bassem, Ng, Denise, Lalazar, Gadi, Rosemore, Carly, Finkelstein, Tova M., Migler, Rachael D., Zheng, Guangrong, Zhang, Peiyi, Jiang, Caroline S., Qureshi, Adam, Vaughan, Roger, Yarchoan, Mark, de Jong, Ype P., Rice, Charles M., Coffino, Philip, Ortiz, Michael V., Zhou, Daohong, Simon, Sanford M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536265/
https://www.ncbi.nlm.nih.gov/pubmed/36073545
http://dx.doi.org/10.1172/jci.insight.161820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536265/
https://www.ncbi.nlm.nih.gov/pubmed/36073545
http://dx.doi.org/10.1172/jci.insight.161820

Ejemplares similares